FDA Grants Accelerated Approval for New Combination Therapy in Advanced Melanoma

The FDA has granted accelerated approval to Tudriqev, an oncolytic viral therapy, combined with nivolumab (Opdivo). This new treatment is for adult patients with unresectable advanced cutaneous melanoma who have progressed after PD-1-blocking antibody regimens. This milestone introduces a novel oncolytic immunotherapy, providing a new option for patients with limited treatment alternatives.